Partnerships and collaborations enable our ability to accelerate the global investigation of novel combination treatments that address major unmet needs and have the potential to improve outcomes for people with cancer around the world.
Strategic partners to advance global development and commercialization activities:
Gilead and Arcus have a 10-year all-in partnership that includes a significant capital investment and equity stake by Gilead into Arcus. Gilead holds co-development and co-commercialization rights to zimberelimab, domvanalimab, etrumadenant and quemliclustat and an option to license current and future molecules.
Taiho has exercised option rights in Japan and other countries in Asia (excluding China) for the majority of Arcus’ clinical portfolio, including domvanalimab, zimberelimab and etrumadenant. Taiho has chosen to participate in two ongoing Phase 3 trials of domvanalimab combinations, STAR-121 in NSCLC and STAR-221 in upper GI cancer.
Clinical collaborations to explore novel combinations
Arcus is interested in clinical collaborations that evaluate novel combinations of Arcus molecules with other companies’ medicines or diagnostics to expand our understanding of important pathways and facilitate global access to expedite development and commercialization.
AstraZeneca and Arcus have a clinical collaboration on Pacific-8 a Phase III study evaluating our anti-TIGIT antibody domvanalimab plus durvalumab (Imfinzi®) for stage 3 non-small cell lung cancer with curative intent